| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Wayne Macfadden, Cherilyn DeSouza, Concetta Crivera, Chris M Kozma, Riad D Dirani, Lian Mao, Stephen C Rodrigue. Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results. BMC psychiatry. vol 11. 2012-04-03. PMID:21999346. |
assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the source study results. |
2012-04-03 |
2023-08-12 |
Not clear |
| Wayne Macfadden, Cherilyn DeSouza, Concetta Crivera, Chris M Kozma, Riad D Dirani, Lian Mao, Stephen C Rodrigue. Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results. BMC psychiatry. vol 11. 2012-04-03. PMID:21999346. |
to evaluate effectiveness outcomes in a real-world setting in patients with schizophrenia initiating risperidone long-acting therapy (rlat). |
2012-04-03 |
2023-08-12 |
Not clear |
| Concetta Crivera, Cherilyn DeSouza, Chris M Kozma, Riad D Dirani, Lian Mao, Wayne Macfadde. Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE). BMC psychiatry. vol 11. 2012-04-03. PMID:21999370. |
resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the schizophrenia outcomes utilization relapse and clinical evaluation (source). |
2012-04-03 |
2023-08-12 |
Not clear |
| Concetta Crivera, Cherilyn DeSouza, Chris M Kozma, Riad D Dirani, Lian Mao, Wayne Macfadde. Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE). BMC psychiatry. vol 11. 2012-04-03. PMID:21999370. |
this analysis examined health care resource utilization from a 24-month observational study of patients with schizophrenia initiated on risperidone long-acting therapy (rlat). |
2012-04-03 |
2023-08-12 |
Not clear |
| Ali Ghaleiha, Navid Honarbakhsh, Mohammad-Ali Boroumand, Morteza Jafarinia, Mina Tabrizi, Farzin Rezaei, Maedeh Raznahan, Shahin Akhondzade. Correlation of adenosinergic activity with superior efficacy of clozapine for treatment of chronic schizophrenia: a double blind randomised trial. Human psychopharmacology. vol 26. issue 2. 2012-03-30. PMID:21412846. |
the authors undertook this study to further evaluate the level of adenosine deaminase (ada) in patients with chronic schizophrenia treated with monotherapy of haloperidol, risperidone or clozapine and correlation between the ada level with response to treatment. |
2012-03-30 |
2023-08-12 |
Not clear |
| Salvatore Gentil. Clinical usefulness of second-generation antipsychotics in treating children and adolescents diagnosed with bipolar or schizophrenic disorders. Paediatric drugs. vol 13. issue 5. 2012-03-28. PMID:21888443. |
nevertheless, the results of this review allow us to suggest the effectiveness of three sgas (aripiprazole, olanzapine, and risperidone) in the short-term treatment of both early-onset schizophrenia and bipolar mania, although such agents show different safety profiles. |
2012-03-28 |
2023-08-12 |
Not clear |
| Jiekun Xuan, Guihua Pan, Yunping Qiu, Lun Yang, Mingming Su, Yumin Liu, Jian Chen, Guoyin Feng, Yiru Fang, Wei Jia, Qinghe Xing, Lin H. Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. Journal of proteome research. vol 10. issue 12. 2012-03-25. PMID:22007635. |
metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. |
2012-03-25 |
2023-08-12 |
Not clear |
| Jiekun Xuan, Guihua Pan, Yunping Qiu, Lun Yang, Mingming Su, Yumin Liu, Jian Chen, Guoyin Feng, Yiru Fang, Wei Jia, Qinghe Xing, Lin H. Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. Journal of proteome research. vol 10. issue 12. 2012-03-25. PMID:22007635. |
in this study, we performed gas chromatography-mass spectrometry based metabolomic profiling in serum of unmedicated schizophrenic patients before and after an 8-week risperidone monotherapy, to detect potential biomarkers associated with schizophrenia and risperidone treatment. |
2012-03-25 |
2023-08-12 |
Not clear |
| Mirjana Doknic, Nadja P Maric, Dubravka Britvic, Sandra Pekic, Aleksandar Damjanovic, Dragana Miljic, Marko Stojanovic, Zoran Radojicic, Miroslava Jasovic Gasic, Vera Popovi. Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone. Neuroendocrinology. vol 94. issue 3. 2012-03-21. PMID:21986470. |
bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone. |
2012-03-21 |
2023-08-12 |
Not clear |
| Hsiang-Hsuan Huang, Ying-Chieh Wang, Chia-Liang Wu, Chen-Jee Hong, Ya-Mei Bai, Shih-Jen Tsai, Ying-Jay Lio. TNF-α -308 G>A polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment. Neuroscience letters. vol 504. issue 3. 2012-03-15. PMID:21967963. |
tnf-α -308 g>a polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment. |
2012-03-15 |
2023-08-12 |
human |
| Hsiang-Hsuan Huang, Ying-Chieh Wang, Chia-Liang Wu, Chen-Jee Hong, Ya-Mei Bai, Shih-Jen Tsai, Ying-Jay Lio. TNF-α -308 G>A polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment. Neuroscience letters. vol 504. issue 3. 2012-03-15. PMID:21967963. |
a total of 500 patients with schizophrenia treated with clozapine (n=275), olanzapine (n=79) or risperidone (n=146) for an average of 49.9 months were recruited. |
2012-03-15 |
2023-08-12 |
human |
| Adam Wichniak, Agnieszka Skowerska, Jolanta Chojnacka-Wójtowicz, Tomasz Tafliński, Aleksandra Wierzbicka, Wojciech Jernajczyk, Marek Jarem. Actigraphic monitoring of activity and rest in schizophrenic patients treated with olanzapine or risperidone. Journal of psychiatric research. vol 45. issue 10. 2012-03-06. PMID:21679968. |
these findings show that patients with schizophrenia treated with olanzapine or risperidone exhibit low physical activity and altered sleep pattern which may promote metabolic side effects. |
2012-03-06 |
2023-08-12 |
Not clear |
| M Nadeem Mazhar, David S Resc. Risperidone induced ventricular tachycardia. Psychopharmacology bulletin. vol 43. issue 3. 2012-03-02. PMID:21150847. |
this is a case report of ventricular tachycardia in a 35 years old african american male being treated with risperidone for schizophrenia. |
2012-03-02 |
2023-08-12 |
Not clear |
| Yael Piontkewitz, Michal Arad, Ina Weine. Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia. Schizophrenia bulletin. vol 37. issue 6. 2012-02-23. PMID:20439320. |
risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia. |
2012-02-23 |
2023-08-12 |
rat |
| Naren Rao, Ganesan Venkatasubramanian, Vinayak Korpade, Rishikesh Behere, Shivarama Varambally, Bangalore Gangadha. Risperidone treatment for polydipsia and hyponatremia in schizophrenia: a case report. Turk psikiyatri dergisi = Turkish journal of psychiatry. vol 22. issue 2. 2012-02-22. PMID:21638234. |
risperidone treatment for polydipsia and hyponatremia in schizophrenia: a case report. |
2012-02-22 |
2023-08-12 |
Not clear |
| Naren Rao, Ganesan Venkatasubramanian, Vinayak Korpade, Rishikesh Behere, Shivarama Varambally, Bangalore Gangadha. Risperidone treatment for polydipsia and hyponatremia in schizophrenia: a case report. Turk psikiyatri dergisi = Turkish journal of psychiatry. vol 22. issue 2. 2012-02-22. PMID:21638234. |
herein we present a schizophrenia case with polydipsia and hyponatremia that was successfully treated with risperidone. |
2012-02-22 |
2023-08-12 |
Not clear |
| Alma Bravo-Mehmedbasi. Risperidone in the treatment of schizophrenia. Medicinski arhiv. vol 65. issue 6. 2012-02-22. PMID:22299296. |
risperidone in the treatment of schizophrenia. |
2012-02-22 |
2023-08-12 |
Not clear |
| Alma Bravo-Mehmedbasi. Risperidone in the treatment of schizophrenia. Medicinski arhiv. vol 65. issue 6. 2012-02-22. PMID:22299296. |
risperidone is well-established medication, with the proven effects on positive and negative symptoms of schizophrenia. |
2012-02-22 |
2023-08-12 |
Not clear |
| Alma Bravo-Mehmedbasi. Risperidone in the treatment of schizophrenia. Medicinski arhiv. vol 65. issue 6. 2012-02-22. PMID:22299296. |
the aim of research was to establish the effectiveness and safety of risperidone in patients with schizophrenia. |
2012-02-22 |
2023-08-12 |
Not clear |
| Andrew Dalton, Tim Lambert, Rudolf Schrover, Judy Hertel, Dell Kingsford Smit. The cost associated with administering risperidone long-acting injections in the Australian community. BMC health services research. vol 11. 2012-02-16. PMID:21943060. |
risperidone long-acting injection (lai) is mostly administered twice weekly to people with schizophrenia by nurses at community mental health centres (cmhc) or through mobile outreach visits. |
2012-02-16 |
2023-08-12 |
Not clear |